NuVision appoints new chair

NuVision Biotherapies has appointed Roger Teasdale as its new chair, following Mark Treherne’s transition from the role to an independent non-executive director.  

Teasdale, who has served as a non-executive director since 2017, commented: ‘I look forward to building on this foundation as we expand into new markets and bring our transformative eye treatments to more people in need.’ 

NuVision’s CEO, Andy Hill, called it ‘a privilege’ to have Teasdale step into the role of chairman, noting that his deep understanding of the company and industry would be crucial in driving innovation and growth.